Olanzapine News and Research

RSS

Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA), the Department of Justice announced today.

19 Jan 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

Study questions use of newer antipsychotic drugs in children

A new study has found that older antipsychotic drugs are as effective as newer ones for some children.

16 Sep 2008

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH).

15 Sep 2008

Antipsychotic drugs get FDA label changes

The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to make safety-related changes to prescribing information, or labeling, to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia.

16 Jun 2008

Spectral Modeling technology substantiated through creation of antipsychotic bank of drug candidates

LIUS Molecular Design is pleased to announce that it has successfully created two antipsychotic drug candidates with third party confirmation of predicted biological activities via in vitro testing.

19 May 2008

Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected

Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.

8 Apr 2008

Aripiprazole has potential for treating alcohol dependence

Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol. Future research will need to examine the beneficial versus the side effects of aripiprazole for treatment of alcohol dependence.

4 Apr 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Treatment of children and adolescents with schizophrenia

There is a wealth of scientific literature available on the treatment of adults diagnosed with schizophrenia.

28 Feb 2008

New schizophrenia treatment

Schizophrenia is one of the most debilitating of the major psychiatric disorders, and is also one of the most difficult to treat.

14 Dec 2007

Novel and inexpensive tool for identifying early signs of schizophrenia

A tendency to extract messages from meaningless noise could be an early sign of schizophrenia, according to a study by Yale School of Medicine researchers.

24 Oct 2007

Little evidence to support therapies for post-traumatic stress disorder

Post-traumatic stress disorder (PTSD) is a severe and ongoing emotional reaction to an extreme psychological trauma; it affects significant numbers of people, in particular military personnel and veterans, who have seen active duty in war zones.

22 Oct 2007

Review of PTSD treatments

Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.

19 Oct 2007

Urgent need for better understanding of bipolar disease in children and adolescents

The number of visits to a doctor's office that resulted in a diagnosis of bipolar disorder in children and adolescents has increased by 40 times over the last decade, reported researchers funded in part by the National Institutes of Health (NIH).

4 Sep 2007

New and very different schizophrenia drug shows promise

Scientists at Eli Lilly say the first human trial of a new schizophrenia drug shows promise for sufferers of the debilitating mental illness.

3 Sep 2007

New treatments for migraines and chronic headaches

Twelve percent of the population, three quarters of them women, suffer at least occasionally from migraines and about 5 percent from chronic headaches.

20 Jun 2007

Chemical maps hint at drug's effects on schizophrenia

Antipsychotic drugs do most of their work in the brain, but they also leave behind in the bloodstream a trail of hundreds of chemicals that may be used in the future to direct better treatment for schizophrenia and other psychiatric conditions, say Duke University Medical Center researchers.

16 May 2007

Lilly to extend patient assistance programs for Medicare patients

Eli Lilly and Company has announced that it will be extending its existing patient assistance program, LillyAnswers, through the end of this year to qualifying patients currently participating in the program, to help bridge the gap in coverage for people who need Lilly medicines, but are not yet enrolled in Medicare Part D.

11 May 2006

Olanzapine appears to lower or delay full-blown psychosis

For young people who clearly seem to be developing early signs of schizophrenia, treatment with the antipsychotic drug olanzapine appears to lower or delay the rate of conversion to full-blown psychosis, according to an article by a Yale School of Medicine researcher in the May issue of The American Journal of Psychiatry.

3 May 2006